{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:14:49Z","timestamp":1786976089414,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd013780","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000}}],"reference-count":65,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013780.pub2","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T07:13:09Z","timestamp":1686208389000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmaceutical policies: effects of policies regulating drug marketing"],"prefix":"10.1002","volume":"2023","author":[{"given":"Izabela","family":"Fulone","sequence":"additional","affiliation":[{"name":"Pharmaceutical Science Graduate Course; University of Sorocaba; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathal","family":"Cadogan","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences; Trinity College Dublin; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Barberato-Filho","sequence":"additional","affiliation":[{"name":"Pharmaceutical Science Graduate Course; University of Sorocaba; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane C\u00e1ssia","family":"Bergamaschi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Science Graduate Course; University of Sorocaba; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren Giustti","family":"Mazzei","sequence":"additional","affiliation":[{"name":"Physical Therapy; University of Sorocaba; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Phillipe","family":"Lopes","sequence":"additional","affiliation":[{"name":"Pharmaceutical Science Graduate Course; University of Sorocaba; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Tolentino","family":"Silva","sequence":"additional","affiliation":[{"name":"Pharmaceutical Science Graduate Course; University of Sorocaba; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciane C","family":"Lopes","sequence":"additional","affiliation":[{"name":"Pharmaceutical Science Graduate Course; University of Sorocaba; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD013780.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1377\/hlthaff.2019.01289","article-title":"The impact of academic medical center policies restricting direct-to-physician marketing on opioid prescribing","volume":"39","author":"Eisenberg","year":"2020","journal-title":"Pharmaceuticals & Medical Technology\u00a0"},{"issue":"7-8","key":"10.1002\/14651858.CD013780.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jpain.2019.12.001","article-title":"The promotion of policy changes restricting access to codeine medicines on Twitter: what do national pain organizations say?","volume":"21","author":"Elphinston","year":"2020","journal-title":"Journal of Pain"},{"issue":"1","key":"10.1002\/14651858.CD013780.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1542\/peds.2007-0819","article-title":"Impact of a 16-community trial to promote judicious antibiotic use in Massachusetts","volume":"121","author":"Finkelstein","year":"2008","journal-title":"Pediatrics"},{"issue":"1\u00a0","key":"10.1002\/14651858.CD013780.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5694\/j.1326-5377.2008.tb01497.x","article-title":"The effect of advertising in clinical software on general practitioners' prescribing behaviour","volume":"188","author":"Henderson","year":"2008","journal-title":"Medical Journal of Australia"},{"issue":"1","key":"10.1002\/14651858.CD013780.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s12913-018-3333-1","article-title":"Promoting quality use of medicines in South-East Asia: reports from country situational analyses","volume":"18","author":"Holloway","year":"2018","journal-title":"BMC Health Services Research"},{"issue":"S3","key":"10.1002\/14651858.CD013780.pub2-BIB0006|cit6","first-page":"158","article-title":"Impact of pharmaceutical cost containment policy changes on the use of antidepressants in Japan","volume":"29","author":"Imai","journal-title":"Pharmacoepidemiology & Drug Safety"},{"issue":"2","key":"10.1002\/14651858.CD013780.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2307\/1966540","article-title":"Impact of social marketing on contraceptive prevalence and cost in Honduras","volume":"23","author":"Janowitz","year":"1992\u00a0","journal-title":"Studies in Family Planning"},{"issue":"6","key":"10.1002\/14651858.CD013780.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1080\/10410236.2019.1584738","article-title":"Consumer's regulatory knowledge of prescription drug advertising and health risk awareness: the moderating role of risk information prominence","volume":"35","author":"Ju","year":"2020","journal-title":"Health Communication"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.socscimed.2016.11.010","article-title":"Gifts and influence: conflict of interest policies and prescribing of psychotropic medications in the United States","volume":"172","author":"King","year":"2017","journal-title":"Social Science & Medicine"},{"issue":"337","key":"10.1002\/14651858.CD013780.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"a1055","DOI":"10.1136\/bmj.a1055","article-title":"Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study","volume":"2","author":"Law","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD013780.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1300\/J371v14n04_05","article-title":"Impact of pharmaceutical policies on promotional targeted drugs","volume":"14","author":"Layton","year":"2006","journal-title":"Journal of Pharmaceutical Finance, Economics and Policy\u00a0"},{"issue":"5","key":"10.1002\/14651858.CD013780.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ahj.2014.01.014","article-title":"Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada","volume":"167","author":"Lu","year":"2014","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2147\/JPR.S163438","article-title":"Do laws impact opioids consumption? A breakpoint analysis based on Italian sales data","volume":"11","author":"Musazzi","year":"2018","journal-title":"Journal of Pain Research"},{"issue":"1","key":"10.1002\/14651858.CD013780.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1186\/s12889-018-6202-2","article-title":"Disease awareness campaigns in printed and online media in Latvia: cross-sectional study on consistency with WHO ethical criteria for medicinal drug promotion and European standards","volume":"18","author":"Alves","year":"2018","journal-title":"BMC Public Health"},{"issue":"4","key":"10.1002\/14651858.CD013780.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s11948-018-0041-5","article-title":"Medicines information and the regulation of the promotion of pharmaceuticals","volume":"25","author":"Alves","year":"2019","journal-title":"Science and Engineering Ethics"},{"issue":"5","key":"10.1002\/14651858.CD013780.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"e1001037","DOI":"10.1371\/journal.pmed.1001037","article-title":"Medical students' exposure to and attitudes about the pharmaceutical industry: a systematic review","volume":"8","author":"Austad","year":"2011","journal-title":"PLOS Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013780.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0018|cit18","doi-asserted-by":"crossref","DOI":"10.1002\/9780470743386","volume-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"issue":"4","key":"10.1002\/14651858.CD013780.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"e0175493","DOI":"10.1371\/journal.pone.0175493","article-title":"Association between physicians' interaction with pharmaceutical companies and their clinical practices: a systematic review and meta-analysis","volume":"12","author":"Brax","year":"2017","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0020|cit20","unstructured":"Bulik BS The top 10 ad spenders in Big Pharma for 2020; April 2021 Available at www.fiercepharma.com\/special-report\/top-10-ad-spenders-big-pharma-for-2020"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0021|cit21","unstructured":"Cardarelli R Licciardone JC Taylor LG A cross-sectional evidence-based review of pharmaceutical promotional marketing brochures and their underlying studies: is what they tell us important and true? Available at www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1450290 10.1186\/1471-2296-7-13"},{"issue":"1","key":"10.1002\/14651858.CD013780.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1211\/ijpp.18.01.0008","article-title":"Direct-to-consumer advertising: Australian pharmacists' experiences with non-prescription medicines","volume":"18","author":"Chaar","year":"2010","journal-title":"International Journal of Pharmacy Practice"},{"issue":"2","key":"10.1002\/14651858.CD013780.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10410236.2019.1584781","article-title":"Direct-to-consumer advertising of prescription drugs and the patient\u2012prescriber encounter: a systematic review","volume":"35","author":"DeFrank","year":"2019","journal-title":"Health Communication"},{"issue":"7","key":"10.1002\/14651858.CD013780.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"e034993","DOI":"10.1136\/bmjopen-2019-034993","article-title":"Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study","volume":"10","author":"Diep","year":"2020","journal-title":"BMJ Open"},{"issue":"7","key":"10.1002\/14651858.CD013780.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMsa070502","article-title":"A decade of direct-to-consumer advertising of prescription drugs","volume":"357","author":"Donohue","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0026|cit26","unstructured":"Data collection form. EPOC resources for review authors, 2017 Available at epoc.cochrane.org\/epoc-specific-resources-review-authors"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0027|cit27","unstructured":"Suggested risk of bias criteria for EPOC reviews. EPOC resources for review authors, 2017 Available at epoc.cochrane.org\/epoc-specific-resources-review-authors"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0028|cit28","unstructured":"EPOC worksheets for preparing a 'Summary of findings' table using GRADE. EPOC resources for review authors, 2017 Available at epoc.cochrane.org\/epoc-specific-resources-review-authors"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0029|cit29","unstructured":"Reporting the effects of an intervention in EPOC reviews. EPOC resources for review authors, 2018 Available at epoc.cochrane.org\/epoc-specific-resources-review-authors"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"l6925","DOI":"10.1136\/bmj.l6925","article-title":"Industry funding of patient and health consumer organisations: systematic review with meta-analysis","volume":"368","author":"Fabbri","year":"2020","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD013780.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"e016408","DOI":"10.1136\/bmjopen-2017-016408","article-title":"Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review","volume":"7","author":"Fickweiler","year":"2017","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0032|cit32","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2020"},{"issue":"5","key":"10.1002\/14651858.CD013780.pub2-BIB0033|cit33","first-page":"325","article-title":"Do gifts from the pharmaceutical industry affect trust in physicians?","volume":"44","author":"Green","year":"2012","journal-title":"Family Medicine"},{"issue":"7650","key":"10.1002\/14651858.CD013780.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD013780.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1057\/palgrave.jmm.5050060","article-title":"Direct-to-consumer advertising of prescription medicines: a systematic review of the evidence from the perspective of the consumer","volume":"7","author":"Harker","year":"2007","journal-title":"Journal of Medical Marketing"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0036|cit36","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"8","key":"10.1002\/14651858.CD013780.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1111\/bcp.13513","article-title":"Drug promotion practices: a review","volume":"84","author":"Jacob","year":"2018","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD013780.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.jclinepi.2014.12.018","article-title":"Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations","volume":"68","author":"Jandoc","year":"2015","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD013780.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/hex.13013","article-title":"Financial relationships between patient and consumer representatives and the health industry: a systematic review","volume":"23","author":"Khabsa","year":"2020","journal-title":"Health Expectations"},{"issue":"16","key":"10.1002\/14651858.CD013780.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1001\/jama.293.16.1995","article-title":"Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial","volume":"293","author":"Kravitz","year":"2005","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0041|cit41","unstructured":"Lexchin J Ziganshina L Regulation of pharmaceutical promotion: why does regulation matter? Available at haiweb.org\/encyclopaedia\/regulation-of-pharmaceutical-promotion-2"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1744-8603-8-24","article-title":"Models for financing the regulation of pharmaceutical promotion","volume":"8","author":"Lexchin","year":"2012","journal-title":"Globalization and Health"},{"issue":"7","key":"10.1002\/14651858.CD013780.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLOS Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013780.pub2-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev-publhealth-031811-124540","article-title":"Advertising of prescription-only medicines to the public: does evidence of benefit counterbalance harm?","volume":"33","author":"Mintzes","year":"2012","journal-title":"Annual Review of Public Health"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1007\/s11606-013-2411-7","article-title":"Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States","volume":"28","author":"Mintzes","year":"2013","journal-title":"Journal of General Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013780.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1108\/JPBM-08-2014-0684","article-title":"Emerging promotional and pricing approaches in the US pharmaceutical market","volume":"23","author":"O\u2019Connor","year":"2014","journal-title":"Journal of Product & Brand Management"},{"issue":"7","key":"10.1002\/14651858.CD013780.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"e6350","DOI":"10.1371\/journal.pone.0006350","article-title":"Quality of pharmaceutical advertisements in medical journals: a systematic review","volume":"4","author":"Othman","year":"2009","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"k1809","DOI":"10.1136\/bmj.k1809","article-title":"Ethical drug marketing criteria for the 21st century","volume":"361","author":"Parker","year":"2018","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD013780.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1017\/s0266462303000576","article-title":"Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies","volume":"19","author":"Ramsay","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0051|cit51","unstructured":"Ratanawijitrasin S Wondemagegnehu E Effective drug regulation: a multicountry study Available at apps.who.int\/iris\/handle\/10665\/42470"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0052|cit52","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2023"},{"issue":"11","key":"10.1002\/14651858.CD013780.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"e1000128","DOI":"10.1371\/journal.pmed.1000128","article-title":"Mandatory disclosure of pharmaceutical industry funded events for health professionals","volume":"6","author":"Robertson","year":"2009","journal-title":"PLOS Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013780.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2105\/AJPH.2010.300027","article-title":"Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices","volume":"101","author":"Rothman","year":"2011","journal-title":"American Journal of Public Health"},{"issue":"1","key":"10.1002\/14651858.CD013780.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jama.2018.19320","article-title":"Medical marketing in the United States, 1997-2016","volume":"321","author":"Schwartz","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD013780.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13584-017-0175-y","article-title":"Strategies for patient empowerment through the promotion of medicines in Israel: regulatory framework for the pharmaceutical industry","volume":"6","author":"Schwartzberg","year":"2017","journal-title":"Israel Journal of Health Policy Research"},{"issue":"10","key":"10.1002\/14651858.CD013780.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"e1000352","DOI":"10.1371\/journal.pmed.1000352","article-title":"Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review","volume":"7","author":"Spurling","year":"2010","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD013780.pub2-BIB0060|cit60","first-page":"669","article-title":"Direct-to-consumer pharmaceutical advertising: therapeutic or toxic?","volume":"36","author":"Ventola","year":"2011","journal-title":"Pharmacy and Therapeutics"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0061|cit61","unstructured":"World Health Organization Ethical criteria for medicinal drug promotion Available at apps.who.int\/iris\/handle\/10665\/38125"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0062|cit62","unstructured":"World Health Organization Drug promotion - what we know, what we have yet to learn: reviews of materials in the WHO\/HAI database on drug promotion Available at apps.who.int\/iris\/handle\/10665\/69177"},{"key":"10.1002\/14651858.CD013780.pub2-BIB0063|cit63","unstructured":"World Bank country and lending groups, country classification data datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups"},{"issue":"2","key":"10.1002\/14651858.CD013780.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"e1001785","DOI":"10.1371\/journal.pmed.1001785","article-title":"Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry self-regulation","volume":"12","author":"Zetterqvist","year":"2015","journal-title":"PLOS Medicine"},{"issue":"11","key":"10.1002\/14651858.CD013780.pub2-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013780","article-title":"Pharmaceutical policies: effects of policies regulating drug marketing","author":"Fulone","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T19:03:22Z","timestamp":1733684602000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013780.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Effective Practice and Organisation of Care Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":65,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013780.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]}}}